Early Lung Cancer Detection

Cizzle Biotechnology (LSE: CIZ) is developing a simple blood test to detect lung cancer early,
when treatment is most effective.

Shareholder Information

Cizzle Biotechnology Holdings plc‘s shares are traded on Main Market of the London Stock Exchange.

Significant Shareholders

As at 08 April 2025, as far as the Directors are aware, the following shareholders have a significant interest in the issued share capital of the Company.

NameNumber of Ordinary Shares% of Issued Share Capital
Hargreaves Lansdown (Nominees) Limited44,809,97711.30
Yorkshire Cancer Research 32,382,3308.17
Interactive Investor Services Nominees Limited31,333,6307.90
Hargreaves Lansdown (Nominees) Limited29,870,0037.54
Hargreaves Landsown (Nominees) Limited28,109,6477.809
Barclays Direct Investing Nominees Limited20,322,9515.13
Interactive Investor Services Nominees Limited19,460,0254.91
HSDL Nominees Ltd17,226,5814.35
Professor Dawn Coverley*17,048,1374.30
HSBC Global Custody Nominee (UK) Limited14,718,2273.71

* the shareholding of Professor Dawn Coverley includes shares held by Dawn’s husband, Dr Juston Ainscough.